Smith & Nephew (SN) Competitors

GBX 1,023.50
-1.50 (-0.15%)
(As of 05/17/2024 ET)

SN vs. CTEC, HIK, HCM, HLN, MXCT, NIOX, EKF, CREO, NCYT, and IUG

Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Haleon (HLN), MaxCyte (MXCT), NIOX Group (NIOX), EKF Diagnostics (EKF), Creo Medical Group (CREO), Novacyt (NCYT), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical" sector.

Smith & Nephew vs.

Smith & Nephew (LON:SN) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.

ConvaTec Group has a net margin of 6.08% compared to Smith & Nephew's net margin of 4.74%. ConvaTec Group's return on equity of 7.89% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew4.74% 5.02% 4.27%
ConvaTec Group 6.08%7.89%4.79%

In the previous week, ConvaTec Group had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 2 mentions for ConvaTec Group and 0 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 0.00 beat ConvaTec Group's score of -0.31 indicating that Smith & Nephew is being referred to more favorably in the media.

Company Overall Sentiment
Smith & Nephew Neutral
ConvaTec Group Neutral

Smith & Nephew has higher revenue and earnings than ConvaTec Group. Smith & Nephew is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£5.55B1.61£263M£0.244,264.58
ConvaTec Group£2.14B2.44£130.30M£0.055,092.00

Smith & Nephew has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, ConvaTec Group has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Smith & Nephew received 206 more outperform votes than ConvaTec Group when rated by MarketBeat users. However, 66.54% of users gave ConvaTec Group an outperform vote while only 62.00% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
558
62.00%
Underperform Votes
342
38.00%
ConvaTec GroupOutperform Votes
352
66.54%
Underperform Votes
177
33.46%

55.7% of Smith & Nephew shares are held by institutional investors. Comparatively, 66.7% of ConvaTec Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 20.1% of ConvaTec Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 2.9%. ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 2.0%. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Smith & Nephew presently has a consensus price target of GBX 1,346.20, suggesting a potential upside of 31.53%. ConvaTec Group has a consensus price target of GBX 307.17, suggesting a potential upside of 20.65%. Given Smith & Nephew's higher possible upside, research analysts plainly believe Smith & Nephew is more favorable than ConvaTec Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
ConvaTec Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

ConvaTec Group beats Smith & Nephew on 13 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SN vs. The Competition

MetricSmith & NephewMedical Devices IndustryMedical SectorLON Exchange
Market Cap£8.95B£2.11B£5.24B£1.79B
Dividend Yield3.03%2.55%44.56%6.58%
P/E Ratio4,264.58246.59129.062,031.99
Price / Sales1.61281.122,373.23400,561.07
Price / Cash18.6815.8136.9827.26
Price / Book1.713.445.512.87
Net Income£263M£69.33M£106.02M£175.46M
7 Day Performance1.89%1.89%1.42%0.84%
1 Month Performance5.86%2.99%4.97%30.02%
1 Year Performance-21.09%101.32%7.93%12.20%

Smith & Nephew Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTEC
ConvaTec Group
1.0324 of 5 stars
GBX 262.20
+0.8%
GBX 307.17
+17.1%
+12.7%£5.38B£2.14B5,244.0010,136News Coverage
HIK
Hikma Pharmaceuticals
0.8382 of 5 stars
GBX 2,002
-0.5%
GBX 2,068.75
+3.3%
+7.5%£4.44B£2.88B2,944.129,100
HCM
HUTCHMED
0 of 5 stars
GBX 344
-1.7%
N/A+48.6%£2.94B£838M3,440.001,988News Coverage
HLN
Haleon
0.1328 of 5 stars
GBX 328.90
+0.2%
GBX 356
+8.2%
-2.5%£30.03B£11.24B2,740.8325,408News Coverage
MXCT
MaxCyte
0 of 5 stars
GBX 378
+1.6%
N/A+23.0%£395.16M£44.05M-1,350.00143
NIOX
NIOX Group
0 of 5 stars
GBX 73.60
-2.1%
GBX 77
+4.6%
+22.0%£312.09M£36.80M3,680.0092Gap Down
EKF
EKF Diagnostics
0 of 5 stars
GBX 33.20
+11.0%
N/A+32.5%£150.64M£52.61M3,320.00356Gap Up
High Trading Volume
CREO
Creo Medical Group
0 of 5 stars
GBX 34.90
-1.1%
N/A+44.1%£126.16M£29.27M-317.27279Gap Down
NCYT
Novacyt
0 of 5 stars
GBX 65
-0.2%
N/A+51.9%£45.91M£7.87M-180.56120
IUG
Intelligent Ultrasound Group
0 of 5 stars
GBX 8.75
+4.9%
N/A-23.2%£28.60M£11.17M-875.0065Gap Up

Related Companies and Tools

This page (LON:SN) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners